Axsome Therapeutics AXSM Debt issuance costs and discount amortization
Debt issuance costs and discount amortization at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's debt issuance costs and discount amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's debt issuance costs and discount amortization?
- Axsome Therapeutics (AXSM) reported debt issuance costs and discount amortization of $159K in Q1 2026.
- How has Axsome Therapeutics's debt issuance costs and discount amortization changed year-over-year?
- Axsome Therapeutics's debt issuance costs and discount amortization decreased by 76.2% year-over-year, from $667K to $159K.
- What is the long-term trend for Axsome Therapeutics's debt issuance costs and discount amortization?
- Over 4 years (2021 to 2025), Axsome Therapeutics's debt issuance costs and discount amortization has grown at a 4.9% compound annual growth rate (CAGR), from $1.08M to $1.3M.
- What does debt issuance costs and discount amortization mean?
- The non-cash adjustment to interest expense related to debt issuance costs.
- How do you interpret debt issuance costs and discount amortization?
- Changes reflect the company's debt structure and the cost of capital over time.
- How does debt issuance costs and discount amortization compare across companies?
- Common for companies with complex capital structures or significant long-term debt.